Gain Therapeutics, Inc. GANX
We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system ("CNS") disorders, lysosomal storage disorders ("LSDs"), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology.
GT-02287 - our lead product candidate, for the treatment of Parkinson's disease, is currently being evaluated in a Phase 1b study in people with Parkinson's disease with or without a GBA1 mutation.
We have generated an extensive preclinical data package providing evidence of the mechanism of action and safety of GT-02287. In preclinical models of GBA1 and idiopathic Parkinson's disease, GT-02287 has been shown to restore glucocerebrosidase, or GCase, function in the lysosome, improve mitochondrial health, reduce toxic lipid substrates and toxic forms of alpha-synuclein, reduce neuroinflammation, improve survival of dopaminergic neurons, increase dopamine levels, completely restore locomotor function and improve cognition, and reduce plasma-based neurodegeneration maker, neurofilament light chain (NfL) back to the level of healthy animals.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $55.2K | $132.6K | $133.9K | $28.9K | — |
| R&D | $10.2M | $10.8M | $11.5M | $8.4M | $7.2M | $2.3M | — |
| SG&A | $8.5M | $9.6M | $10.8M | $9.5M | $6.8M | $1.2M | — |
| Total operating expenses | $18.7M | $20.4M | $22.3M | $17.9M | $14.0M | $3.5M | — |
| Operating income | -$18.7M | -$20.4M | -$22.3M | -$17.8M | -$13.8M | -$3.5M | — |
| Interest expense | — | — | $494.2K | $375.4K | $12.5K | $3.6K | — |
| Pre-tax income | -$19.3M | -$19.9M | -$22.2M | -$17.5M | -$13.9M | -$3.6M | — |
| Income tax | $861.1K | $536.8K | $79.3K | $93.0K | $4.0K | $5.4K | — |
| Net income | -$20.2M | -$20.4M | -$22.3M | -$17.6M | -$13.9M | -$3.6M | — |
| EPS, basic | -0.61 | -0.89 | -1.71 | -1.48 | -1.37 | -1.33 | — |
| EPS, diluted | -0.61 | -0.89 | -1.71 | -1.48 | -1.37 | -1.33 | — |
| Shares, diluted (wtd. avg.) | 33.0M | 22.9M | 13.0M | 11.9M | 10.2M | 2.7M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.8M | $10.4M | $11.8M | $7.3M | $36.9M | $7.5M | $313.7K |
| Short-term investments | — | — | $5.0M | $12.8M | — | — | — |
| Receivables | — | — | — | — | — | $8.5K | — |
| Total current assets | $22.2M | $11.6M | $17.8M | $21.1M | $37.7M | $9.0M | — |
| Property, plant and equipment | $74.9K | $103.6K | $126.0K | $144.4K | $106.0K | $29.6K | — |
| Total assets | $22.8M | $12.1M | $18.6M | $24.1M | $39.0M | $9.6M | — |
| Accounts payable | $825.0K | $946.3K | $1.3M | $1.6M | $560.5K | $961.5K | — |
| Short-term debt | $100.9K | $110.2K | $118.8K | $108.1K | $103.8K | $22.6K | — |
| Total current liabilities | $3.4M | $3.9M | $4.9M | $4.1M | $2.6M | $2.1M | — |
| Long-term debt | $300.1K | $328.3K | $449.1K | $495.3K | $590.5K | $715.7K | — |
| Total liabilities | $4.3M | $4.8M | $6.0M | $5.2M | $4.2M | $3.4M | — |
| Retained earnings | -$81.2M | -$60.8M | -$38.5M | -$20.9M | -$7.0M | -$3.5M | — |
| Total equity | $18.6M | $7.3M | $12.6M | $18.9M | $34.8M | $6.2M | -$449.9K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.5M | -$18.9M | -$18.9M | -$14.7M | -$12.4M | -$3.2M | — |
| Depreciation and amortisation | $94.0K | $84.1K | $83.6K | $64.2K | $15.5K | $9.6K | — |
| Stock-based compensation | $1.8M | $2.4M | $3.3M | $1.5M | $839.4K | $81.6K | — |
| Capital expenditure | — | $22.5K | $15.4K | $119.0K | $94.2K | $20.8K | — |
| Investing cash flow | — | $5.0M | $10.2M | -$14.8M | -$94.2K | -$20.8K | — |
| Financing cash flow | $28.4M | $13.0M | $12.6M | -$78.8K | $41.8M | $10.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-035188.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $28.9K | $133.9K | $132.6K | $55.2K | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$3.6M | -$13.9M | -$17.6M | -$22.3M | -$20.4M | -$20.2M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |